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Chapter
Amino Acids Profiling for the 
Diagnosis of Metabolic Disorders
Yana Sandlers
Abstract
Inborn errors of metabolism (IEM) represent a group of inherited diseases in 
which genetic defect leads to the block on a metabolic pathway, resulting in a single 
enzyme dysfunction. As a downstream consequence of the residual or full loss of the 
enzymatic activity, there is an accumulation of toxic metabolites in the proximity of 
the metabolic block and/or a deficiency of an essential metabolic product which leads 
to the clinical presentation of the disease. While individually IEMs are rare, a collec-
tively estimated incidence of metabolic inherited disorders is 1:800. The genetic basis 
of IEMs can involve abnormalities such as point mutations, deletions or insertions, 
or more complex genomic rearrangements. Categorization of IEM can be simply 
made on the basis of the affected metabolic network: fatty acids oxidation disorders, 
protein/amino acids metabolism disorders, disorders of carbohydrate metabolism, 
lysosomal storage diseases, peroxisomal disorders, and mitochondrial diseases. This 
chapter will overview amino acid metabolism-related inherited disorders and amino 
acid analysis for the diagnosis and routine monitoring of this category of IEMs.
Keywords: inborn error of metabolism, amino acids disorders, quantitative amino 
acids analysis, ion exchange chromatography, mass spectrometry
1. Introduction
Amino acids (Figure 1) play multiple important roles in our body: they are basic 
structural protein units and precursors of neurotransmitters, porphyrins, and nitric 
oxide. Furthermore, amino acids derived from the dietary proteins serve as energy 
source since while catabolized in our body, amino acids form organic acids that can 
replenish Krebs cycle and ammonia that eliminates through urea cycle [1].
Amino acids disorders (also called aminoacidopathies) are a group of inborn 
errors of metabolism diseases, caused by the inherited defects in pathways involved 
in amino acids metabolism. All primary amino acids disorders (Table 1) follow an 
autosomal recessive mode of inheritance which means that the mutation caused 
a metabolic block is present in the genetic material of both parents. As a result of 
mutation, the inherited defect is reflected downstream as a lack or a partial biologi-
cal activity of enzymes involved in amino acids metabolism. Consequently, some 
substrates in these pathways accumulate or are diverted into alternative pathways. 
Therefore, amino acids disorders are biochemically characterized by abnormal 
levels of single or several amino acids and their downstream plasma and/or urine 
metabolites (Tables 2–6). Amino acid disorders are presented with variable and 
often nonspecific clinical symptoms. In conjunction with medical support, these 
disorders are managed by nutritional restrictions, supplements and medical 
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foods that limit consumption of an offending amino acid or in some cases protein 
consumption. It is important therefore routinely perform amino acids’ analysis to 
monitor dietary treatment outcomes in already diagnosed individuals. In the next 
chapters, primary amino acids disorders are reviewed and quantitative amino acid 
analysis in clinical settings is discussed.
1.1 Phenylketonuria
Phenylketonuria (commonly known as PKU, incidence 1 in 13,500–19,000 births 
in the United States [2]) is an inherited disorder of phenylalanine metabolism charac-
terized by phenylalanine hydroxylase deficiency (Figure 1). The enzyme catalyzes the 
conversion of phenylalanine to tyrosine in the presence of tetrahydrobiopterin (BH4) 
as a cofactor. Based on plasma phenylalanine level, PKU is categorized by severe 
(Phe > 1200 μmol/L), mild (Phe = 600–1200 μmol/L) and hyperphenylalaninemia 
(above the normal cut off but below 600 μmol/L) phenotypes. Clinically PKU can be 
presented with growth failure, global developmental delay, severe intellectual disabil-
ities and other severe symptoms. During pregnancy, elevated levels of phenylalanine 
have teratogenic effects on the developing fetus [3] and the condition is recognized 
as maternal PKU. Phenylalanine accumulation is also seen in defects of biopterin 
cofactor biosynthesis and regeneration [4] (Table 1). Nutritional management of 
PKU targets excessive accumulation of phenylalanine by restriction of natural protein 
intake in combination with the use of phenylalanine-free protein substitutes.
1.2 Disorders of tyrosine metabolism
Tyrosine metabolic pathway consists of five enzymatic reactions taking place 
mainly in hepatocytes and renal proximal tubules. Tyrosinemia I is the most severe 
inherited disorder of tyrosine metabolism caused by a deficiency of fumarylaceto-
acetate hydrolase, the last enzyme in the tyrosine catabolic pathway. The disorder 
has a high incidence in French Canadian ethnicity [5] and involves hepatorenal 
dysfunction. Tyrosinemia II is caused by a deficiency of the hepatic tyrosine 
aminotransferase and manifested by mental retardation and other severe symptoms 
[6]. A deficiency in the activity of 4-hydroxyphenylpyruvate dioxygenase leads to 
tyrosinemia III, a rare disorder characterized by mild mental retardation and/or 
convulsions [7, 8]. All three disorders biochemically characterized by high levels of 
plasma tyrosine (hypertyrosinemia) and urine excretion of downstream tyrosine 
metabolites (Table 1). Elevated plasma tyrosine can also be seen due to vitamin-C 
responsive transient tyrosinemia during the neonatal period (Figure 2).
Figure 1. 
The general structure of amino acids consist of an amino group, a carboxylic group and a variable R side chain 
that has a major effect on solubility and polarity.
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Aromatic amino acids disorders
Disorder name Amino acid 
involved
Enzyme or 
transport 
defect
Additional biomarkers
PKU classical Phe (B) high PAH Phe: Tyr ratio (B), phenylpyruvic, phenyllactic 
and 2-hydroxyphenylacetic acids (U)
Defect of 
biopterin cofactor 
biosynthesis
Phe (B) high GTPCH Low biopterin, neopterin (U)
Defect of 
biopterin cofactor 
biosynthesis
Phe (B) high PTPS Low biopterin, high neopterin (U)
Defect of 
biopterin cofactor 
regeneration
Phe (B) high PCBD1 High neopterin and primapterin (U)
Defect of 
biopterin cofactor 
regeneration
Phe (B) high DHPR High biopterin (U) and low DHPR activity in 
dried blood spots
Tyrosinemia I Tyr (B) high FAH Succinylacetone (DBS, U), 4-hydroxy-
phenylpyruvic, 4-hydroxy-phenyllactic acids 
(U)
Tyrosinemia II Tyr (B) high TAT 4-hydroxyphenylpyruvic, 4-hydroxy-
phenyllactic acids (U)
Tyrosinemia III Tyr (B) high HPPD 4-hydroxyphenylpyruvic, 
4-hydroxyphenyllactic acids (U)
PAH, phenylalanine hydroxylase; GTPCH, GTP cyclohydrolase; PTPS, 6-pyrovoyltetrahydropterin synthase; PCBD1, 
pterin-4a-carbinolamine dehydratase; DHPR, dihydropterin reductase; FAH, fumarylacetoacetate hydrolase; TAT, 
tyrosine aminotransferase; HPPD, 4-hydroxyphenylpyruvate dioxygenase.
Table 1. 
Laboratory findings in aromatic amino acids disorders.
Figure 2. 
Reaction catalyzed by phenylalanine hydroxylase. Tetrahydrobiopterin (BH4) is a co-factor of PAH. DHPR, 
dihydropteridine reductase; PCBD1, pterin-4-α-carbinolamine dehydratase.
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1.3 Maple syrup urine disease
Maple syrup urine disease is a disorder of branch chain amino acids metabolism 
caused by a deficiency of branched-chain α-keto acid dehydrogenase complex. 
MSUD is presented with five clinical phenotypes on the basis of the age at onset, the 
severity of symptoms and response to thiamine supplementation [9]. MSUD char-
acterized biochemically by elevated plasma branched-chain amino acids (leucine, 
isoleucine, valine, allo-isoleucine) and their abnormal ratio (normal ratio is valine:is
oleucine:leucine/3.5:1:2). The disease is managed by dietary leucine restriction, thus 
all branch chain amino acids and allo-isoleucine are routinely monitored. The classic 
MSUD is the most severe form of the disease characterized by no or very low residual 
enzyme activity and clinically manifested by developmental and neurological delays, 
encephalopathy, feeding problems, and a characteristic maple syrup odor in urine.
1.4 Urea cycle disorders
During protein catabolism, amino acids’ carbon skeleton is metabolized to 
gluconeogenic and/or ketogenic precursors whereas nitrogen group is converted to 
ammonia through the deamination process. Toxic ammonia derived from amino 
acids and other metabolic sources is entering the urea cycle and further is converted 
to the readily excreted and nontoxic urea. The cycle takes place in the liver and a defi-
ciency of any enzymes or transporters involved in the urea cycle can cause ammonia 
accumulation (hyperammonemia) which has a highly toxic effect on the central 
nervous system. The overall estimated incidence of urea cycle disorders is 1:8000. All 
urea cycle disorders have an autosomal recessive inheritance, with the exception of 
ornithine-transcarbamylase deficiency (OTCD), which is X-linked. Plasma citrulline 
is a key amino acid in the biochemical diagnosis of urea cycle defects (Table 3).
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome 
is caused by the mutations in the SLC25A15 or ORNT1 gene which result in the 
deficiency of ornithine translocase. The protein transports ornithine, lysine, 
and arginine across the inner mitochondrial membrane in peripheral tissues and 
pericentral hepatocytes. ORC1 deficiency reduces the availability of mitochondrial 
ornithine, which leads to the ornithine increase in the cytosol (hyperornithinemia). 
In the liver, since the mitochondrial ornithine is a required substrate for ornithine 
transcarbamylase (OTC), the reduced level of mitochondrial ornithine slows down 
flux through the urea cycle (Figure 3). As a result of the reduced capacity of the 
urea cycle, ammonia and carbamoyl-phosphate levels increase (hyperammonemia). 
At the same time, an excess of carbamoyl-phosphate is diverted to react with lysine 
to form homocitrulline (homocitrullinuria) or enters in the pyrimidine pathway, 
to form orotic acid which is later excreted in urine. Similarly, as for other urea cycle 
disorders, early diagnosis in infancy may improve the clinical outcome of HHH.
Disorders branched-chain amino acids
Disorder 
name
Amino acid 
involved
Enzyme or 
transport 
defect
Additional biomarkers
MSUD BCAA (B) high, 
allo-Ile (B) high
BCKDC Plasma ratio of Val:Ile:Leu (3.5:1:2), branch chain 
2-ketoacids and 2-hydroxyacids (U)
BCKDC, branched-chain ketoacid dehydrogenase complex.
Table 2. 
Laboratory findings in MSUD.
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Urea cycle disorders
Disorder name Amino acid 
involved
Enzyme or 
transport defect
Additional biomarkers
Citrullinimia I Cit (B) markedly 
elevated
ASS Hyperammonemia, 
orotic acid (U), can be 
accompanied by high 
glutamine and alanine (B)
Citrullinimia II/citrin 
deficiency
Cit (B) moderate 
high, Met, Lys (B)
Asp/Glu 
mitochondrial 
exchanger
Hyperammonemia, orotic 
acid (U). Citrulline is 
moderately elevated
CPS-I deficiency Cit (B) low CPS1 Can be accompanied 
by high glutamine and 
alanine (B)
Ornithine 
transcarbamylase 
deficiency
Cit (B) low OTC Nonspecific amino 
acid profile: increased 
glutamine, alanine and 
decreased ornithine, 
arginine (B). Orotic acid 
(U) markedly increased
Arginino-succinic 
acidemia
ASA (B), (U) 
elevated
ASL Low citrulline, low 
arginine (B)
Argininemia Arg (B) high Arginase Orotic acid (U), Normal or 
reduced citrulline (B)
HHH Orn (B, U), high ORC1 Homocitrulline (U) high
Co-factor producing 
N-acetyl glutamate 
synthetase deficiency
Gln (B) high NAGS Cit (B) low, alanine high 
(B)
B, blood; U, urine.
Table 3. 
Laboratory findings in urea cycle disorders.
Figure 3. 
Urea cycle. ARG, arginase; ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; CPS1, 
carbamoylphosphate I synthase; ORNT 1, mitochondrial ornithine transporter; OTC, ornithine 
transcarbamylase.
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1.5 Disorders of sulfur amino acids metabolism
Homocystinuria is a disorder of methionine metabolism (Figure 4). The main 
biochemical finding in homocystinuria is accumulation of a sulfur-containing 
amino acid homocysteine and its metabolites in the blood and urine. Homocysteine 
is formed from methionine via transmethylation. Once generated homocysteine can 
be irreversibly degraded via transsulfuration pathway to cysteine or remethylated 
back to methionine by methionine synthase. Remethylation involves a transfer of 
methyl group from 5-methyltetrahydrofolate to homocysteine via cobalamin (Cbl)-
dependent methionine synthase (MT) and links folate cycle and homocysteine 
pathway. Homocysteine can also be remethylated through an additional pathway 
which involves liver and kidney betaine-homocysteine methyltransferase. Defects 
in any of these steps can result in homocystinuria. The classic homocystinuria is 
caused by cystathionine β-synthase (CBS) deficiency [10], a key enzyme in the 
trans-sulfuration pathway that converts homocysteine into cystathionine. A block 
at cystathionine β-synthase limits transsulfuration to the cysteine and results 
in both increased homocysteine and methionine, the latter caused by enhanced 
remethylation. The remethylation homocystinuria disorders include methylene-
tetrahydrofolate reductase deficiency (MTHFR) and defects of cobalamin (Cbl) 
metabolism [11]. It has to be noted that methionine and not homocysteine is 
analyzed through the newborn screening, thus, MTHFR disorder and the cobala-
min defects may not be detected because methionine level in these disorders can be 
normal. To increase the detection rate in cobalamin related disorders and MTHFR, 
some studies report a benefit of adding total homocysteine analysis to the diagnos-
tic workflow [12]. Total homocysteine is defined as the sum of all homocysteine 
species in plasma/serum, including free and protein-bound forms. The measure-
ment of total homocysteine requires an immediate separation and freezing of the 
collected plasma.
Figure 4. 
Sulfur amino acids metabolism. CBS, cystathionine β synthase; Cbl, cobalamin; SAM, S-adenosyl methionine; 
SAH, S-adenosylhomocysteine; MAT, methionine adenosyltransferase; MS, methionine synthase; MTHFR, 
methylene tetrahydrofolate reductase; THF, tetrahydrofolate.
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1.6 Nonketotic hyperglycemia
Nonketotic hyperglycemia (NKH) is a severe disorder of glycine metabolism. 
Glycine is catabolized through the four-peptide cleavage complex. P-protein, a 
pyridoxal phosphate-containing protein, T-protein, a protein required for the 
tetrahydrofolate-dependent reaction, H-protein, a protein that carries the amino-
methyl intermediate and then hydrogen through the prosthetic lipoyl moiety, and 
L-protein, a lipoamide dehydrogenase. The disorder is so severe, that most of the 
affected individuals die within few months of life or survive with significant intellec-
tual disabilities. Main laboratory findings in NKH is plasma and CSF elevated glycine.
Disorders of amino acids transport
Disorder name Amino acid 
involved
Enzyme/transport defect Additional biomarkers
Cystinuria Cystine (U) 
elevated
Cystine and dibasic amino acids 
in GI tract and renal tubule
Lysine, ornithine, arginine 
increase (U)
Lysinuric protein 
intolerance
Lys (U) 
markedly 
elevated
Cationic amino acids 
transporter SLC7A7
Arginine, ornithine 
moderate increase (U), 
orotic acid (U)
Fanconi 
syndrome
All amino acids 
elevated (U)
Defects in proximal renal tubule
U, urine.
Table 5. 
Laboratory findings in renal aminoacidurias.
Disorders of sulfur amino acids
Disorder name Amino acid 
involved
Enzyme or 
transport 
defect
Additional biomarkers
Homocystenuria Free 
homocystine  
(B, U) high
CBS Total Hcy and methionine (B, U)
S-Adenosyl-
homocysteine-
hydroxylase deficiency
Met (B) high AdoHcyas Mildly elevated total plasma Hcy, 
S-adenosylhomocysteine, (B), 
S-adenosylmethionine (B)
Sulfate oxydase 
deficiency
SSC* (B, U) high SUOX Taurine, low cystine (B, U)
Molybden cofactor 
deficiency
SSC* (B, U) high SUOX, 
XDH, AO
Taurine, low cystine (B, U), elevated 
hypoxanthine and xanthine (U), low 
uric acid (B)
Glycine-N-
methyltransferase 
deficiency
Met (B) high GNMT S-adenosylmethionine (B)
Hyper-methioninemia Met (B) high MAT
CBS, cystathionine beta synthase; AdoHcyas, S-adenosylhomocysteine hydroxylase; SUOX, sulfate oxidase; XDH, 
xanthine dehydrogenase; AO, aldehyde oxidase; GNMT, glycine-N-methyltransferase.
*S-sulphocysteine may not be detectable in plasma using routine methods in sulfite oxidase and molybdenum co-factor 
deficiencies.
Table 4. 
Laboratory findings in disorders of sulfur amino acids.
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1.7 Renal aminoacidurias
Renal aminoacidurias are disorders have inherited defects that affect renal 
tubular reabsorption process. Thus these disorders are characterized by abnormal 
urinary amino acids.
2. Newborn screening
Early diagnosis may prevent serious implications of inborn errors of metabolism, 
including amino acids disorders and significantly decrease morbidity and mortality. 
Newborn screening is a public health program that facilities early diagnosis by identi-
fying neonates with potential treatable inborn errors of metabolism at the very early 
stages of their lives [13, 14]. This practice helps to manage the disease even for neonates 
that do not have evident symptoms in the first days of their lives. Amino acids analysis 
has always been an important part of the newborn screening. The first PKU screening 
bacterial inhibition assay was invented by Robert Guthrie in the early '60s [15]. Since 
that time, screening for IEMs is performed worldwide. In the United States, newborn 
screening is a state-mandated public health program ensuring that all newborns are 
screened for certain inherited conditions at birth. The panel of screening conditions 
varies from state to state. The advisory committee on heritable disorders in newborns 
and children advises the Secretary of Health and human services uniform screening 
panel, which currently consist of 34 core disorders and 26 secondary disorders. The 
recommended panel includes multiple amino acids related disorders (Table 7).
3. Quantitative amino acids analysis
Quantitative amino acids analysis is an important tool for diagnosis of amino acids 
disorders and nutritional monitoring of individuals with already established diagno-
sis. Amino acids can be detected in most biological fluids, however, the most common 
Recommended 
uniform screening 
panel (RUSP)
Argininosuccinate aciduria, citrullinemia type I homocystinuria 
(cystathionine-β-synthase), maple syrup urine disease, phenylketonuria/
hyperphenylalaninemia, tyrosinemia I
Additional non-
RUSP conditions
Nonketotic hyperglycinemia (NKH), prolinemia, hyperammonemia/ornithinemia/
citrullinemia (HHH)
Secondary Defects of biopterin cofactor biosynthesis and regeneration, citrullinemia II, 
hypermethioninemia, tyrosinemia II, tyrosinemia III
Table 7. 
List of amino acids disorders that are recommended by the Secretary of the Department of Health and Human 
Services (HHS) as a part of state universal newborn screening (NBS) program effective July 2018.
Disorder of glycine metabolism
Disorder name Amino acid 
involved
Enzyme/transport defect Additional biomarkers
Nonketotic hyperglycemia 
(NKH)
Gly (B, 
CSF) high
Mutations in Gly cleavage 
system
Increased CSF/plasma 
Gly ratio
B, blood; CSF, cerebrospinal fluid.
Table 6. 
Laboratory findings in NKH.
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fluids for inborn errors of metabolism diagnostics and monitoring are blood, plasma, 
and urine. In some cases, cerebrospinal fluid (CSF) amino acid levels are also diag-
nostic (Table 5). Although each disorder is biochemically characterized by abnormal 
levels of a single or a few amino acids, quantitative a non-screening analysis, and 
interpretation is not restricted to those metabolites and consist from a panel of nearly 
40 amino acids and specific ratios. For example, along with plasma phenylalanine 
level, it is important also to assess plasma phenylalanine/tyrosine ratio that can be 
used to differentiate between PKU and non-PKU hyperphenylalaninemia [16].
3.1 Factors affecting amino acid analysis
The different chemical characteristics, a wide range of normal physiological 
levels [17–19], age groups variability and other factors detailed below represent a 
significant analytical challenge for the amino acid analysis. Diet is one of the  
significant factors that can highly affect amino acids levels [20, 21]. For example, 
meat and poultry consumption leads to increased excretion of β alanine and 
1-methylhistidine. Thus blood collection intended for amino acids analysis is 
recommended after overnight fasting. Other factors such as urinary bacterial 
contamination can significantly alter urinary amino acids profile [22]. Some drugs 
interfere with amino acids metabolism [23] or cause signal artifacts. Valproic acid, 
for example, can cause an increase in plasma glycine. Anticoagulants used dur-
ing sample collection also can contain interfering constituents [24]. For example, 
blood collection tubes containing sodium bisulfate in addition to heparin can 
yield a peak of S-sulfocysteine, falsely suggesting sulfite oxidase deficiency. 
Ethylenediaminetetraacetic acid (EDTA) additive in collection tube can produce 
ninhydrin-positive peaks, therefore lithium-heparin coated tubes are strongly 
preferred for the blood collection. An additional interfering factor to the amino acid 
analysis is a hemolysis as it may lead to the decrease of arginine with simultaneous 
increase of ornithine due to red blood cells arginase activity, and an increase in 
taurine that released from leukocytes and platelets. Serum is usually not a choice for 
the amino acids analysis, because blood needs to clot at room temperature during 
which asparagine is converted to aspartic acid and glutamine to glutamic acid.
For the urine analysis, a 24-h urine collection is preferred, alternatively, an 
overnight collection can be sufficient for the diagnostic purposes. In order to avoid 
artifacts, no preservatives are added to the urine sample.
Overall, during a prolong sample storage glutamine and asparagine decrease 
whereas glutamic and aspartic acids increase simultaneously. Additional markers 
of prolong storage are an increase of ethanolamine derived from phosphoethanol-
amine decomposition, increased tryptophan, GABA and taurine.
When cerebrospinal fluid is used for the analysis, it must be not contaminated 
with blood, as it leads to the nonspecific increase of multiple amino acids and can 
mask diagnostic findings.
Quantitative amino acids analysis implies in a variety of nonclinical fields such 
as biomedical research, bioengineering, food science, and agriculture. Multiple 
analytical methods have been developed over the years, however, some of these 
methods are not cost effective and labor intensive and thus are not applicable in 
clinical settings. The aim of next paragraphs is to describe the most common and 
widely used platforms in laboratory medicine field.
3.2 Ion exchange chromatography coupled with optical detection
In early 50s, diagnostic quantitative amino acid analysis became feasible with 
Moore and Stein publication on plasma amino acids separation with polystyrene 
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resin column [25] and the subsequent automatization of the technique [26]. 
The principle, called ion exchange chromatography (IEC) with a post-column 
derivatization, for a long time remained a gold standard for the clinical amino 
acids analysis. Nowadays, despite the methodological advancements, the ion 
exchange chromatography using a lithium buffer system, followed the post-column 
derivatization with ninhydrin and UV detection is still widely used in clinical 
setting.
Standard sample preparation for IEC amino acid analysis involves deproteiniza-
tion with 35% (w/v) sulfosalicylic acid (SSA) added to the biological fluid. It is 
recommended to use one volume of SSA to 10 volumes of plasma. A fixed amount 
of non-physiological amino acid as an internal standard is added to all samples. 
Commonly used internal standards are d-glucosaminic acid, S-2-aminoethyl-
1-cysteine, norvaline, and norleucine, however, norleucine can interfere with 
argininosuccinic acid peak. After a short incubation, centrifugation and filtration, 
the sample is ready for the injection and separation.
In IEC, the separation is driven by the ionic interactions between the amino acid 
and functional ligands linked to the stationary phase of the column. The chromato-
graphic column is filled with negatively charged resins. The sample is loaded on the 
column in low acidic pH and at this point, all amino acids bear a positive charge and 
strongly interact with the column. Manipulation with a lithium buffer composition 
during the run alters pH and salt composition, and as a result, there is a change in 
amino acid charge status (Figure 5). As the isoelectric point is reached amino acid is 
not charged anymore and has weak interactions with the charged column.
The complex separation of multiple amino acids is achieved based on ionic 
interactions strength. Amino acids with the weakest ionic interactions to the 
column start to elute first. After column elution, amino acids are mixed with a 
post-column reagent and are optically detected. The most common and well-
established post-column derivatization is reaction with ninhydrin that produces a 
purple Ruhemann’s chromophore (λmax = 570 nm, Figure 6) for α-amino acids and 
yellow product with secondary amines (λmax = 440 nm) for such as proline and 
 hydroxyproline [27].
The absorbance intensity of the produced colorful analyte originated from 
every eluted amino acid is proportional to the amino acid’s concentration in 
the examined biological fluid. Despite the fact that IEC amino acids technique 
is highly reproducible with a good linearity over a broad range, it suffers from 
a long run time for the full amino acids profile (about 150 min), and a lack 
of specificity as amino acids identification is based solely on retention time. 
Furthermore, co-elution of some amino acids on standard IEC method is 
Figure 5. 
Aspartic acid charge in different pH.
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observed. For example, homocitrulline co-elutes with methionine and make 
challenging HHH syndrome. Moreover, allo-isoleucine, a diagnostic market for 
MSUD co-elutes with cystathionine. Argininosuccinic acid that accumulates in 
patients with argininosuccinate lyase deficiency has the same retention time as 
leucine. Additional drawback of the methodology is a limited stability of ninhy-
drin (recommended storage of the working solution ≤1 month) which adds up to 
the cost of the analysis.
3.3 RP-HPLC and RP-UPLC techniques
In recent years, reverse-phase high-performance liquid chromatography 
(RP-HPLC) and ultra-high performance liquid chromatography (UPLC) meth-
ods emerged as an alternative to the ion exchange chromatography. In RP-HPLC 
methods, the separation is based on hydrophobic interactions between the 
analyzed amino acid in the mobile phase and the immobilized hydrophobic 
ligands attached to the nonpolar column stationary phase. RP-HPLC offers 
a great resolution of very closely related molecules under a wide range of 
chromatographic conditions. For the optical detection, derivatization with 
o-phthalaldehyde (OPA) can be used as a pre-column or a post-column reaction. 
During the reaction, in the presence of thiol such as 2-mercaptoethanol, a stable 
fluorescent product is produced and can be detected by fluorimetry (excitation 
340 nm and emission 410 nm) or UV (340 nm) [28, 29]. Although reproducible 
and automated [30], OPA derivatization method is not a good choice for pro-
line/hydroxyproline and sulfur-containing amino acids detection. Alternative 
reagents for RP-HPLC with pre-column derivatization are phenylisothiocyanate 
(PITC, Pico-Tag commercialized by Waters) [31], dimethylamino-azoben-
zenesulfonyl-chloride (DABS-Cl) [32] and 9-fluorenylmethylchloroformate 
(FMOC-Cl) [33].
More advanced UPLC systems employ a small particle size (typically 1.7 μM) and 
a high pH range stable columns. These systems use less solvent and are operated in a 
high pressure which allows an excellent resolution achieved in a short time frame and 
thus potentially decreases turnaround time per sample. Narayan et al. analyzed 170 
patient samples by pre-column 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
(AQC) derivatization (Figure 7) followed by reverse phase UPLC [34] and com-
pared amino acids data to the traditional amino acids analyzer operated through ion 
Figure 6. 
Ninhydrin reaction with amino acid to produce Ruhemann’s purple.
Figure 7. 
AQC reaction with amino acid.
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exchange chromatography method. The study found that UPLC method is compa-
rable to the reference IEC and thus adaptable to the clinical laboratory.
Peake et al. developed a modified RP-UPLC method and achieved a better reso-
lution for tyrosine, glycine, arginine and homocitrulline peaks [35]. The improved 
method also provides enhanced resolution to separate ornithine from mesocys-
tathionine. There is a high clinical significance to accurate ornithine analysis as 
ornithine’s levels are diagnostic for hyperornithinemia-hyperammonemia- 
homocitrullinemia (HHH) syndrome. The developed UPLC method has several 
advantages. Due to the short analysis time, it is feasible to include calibration 
prior to the analysis of urgent samples with a special turnaround times. Overall, 
RP-UPLC decreases turnaround time per sample, however, commercial kit com-
ponents have a very limited shelf life and thus the method is not cost effective for 
clinical laboratories with a small samples volume.
Overall, ion exchange chromatography, RP-HPLC, and RP-UPLC techniques 
have a good reproducibility and a high sensitivity in the low picomole range, how-
ever, they all are carried out with optical detection. The main drawback of this type 
of detection is a lack of specificity as amino acids identification is solely based on 
the retention time. This can potentially cause to the false findings. For example, in a 
standard ion exchange chromatography method, ampicillin and amoxicillin co-elute 
with phenylalanine and it can be reported as falsely elevated.
3.4 Flow infusion tandem mass spectrometry (FIA-MS/MS)
More recently, developments and advancements in mass spectrometry field 
led to the inclusion of tandem mass spectrometry (MS/MS) as an alternative high 
throughput and specific technique for the amino acids analysis. It is also feasible 
to separate amino acids by liquid chromatography prior to the mass spectrometry 
analysis, however, it is time-consuming in clinical settings. Instead, tandem mass 
spectrometry scans are used for the high throughput, cost-effective amino acids 
analysis. It has to be noted, that FIA-MS/MS is a screening analysis that widely 
implemented through the newborn screening initiative.
For the newborn screening, blood samples are typically collected on filter paper 
and a defined size (typically 3 mm) disks are punched out of the paper and are 
extracted. The early assays required derivatization by butylation (Figure 8) in order 
to improve detection limits and minimize ion suppression effects in a complex bio-
logical matrix. Currently, to increase a throughput, some clinical laboratories skip 
on the derivatization step. Extracted and derivatized samples are directly intro-
duced by injection to the mass spectrometer instrument with no chromatographic 
separation. Usually, 5–10 μl of a sample is injected into a flowing solvent at a very 
low (20–50 μl) flow rate. All screened amino acids (Table 8) are eluting at the same 
time whereas a typical run time is 1.5–2 min per sample. Every analyzed amino acid 
is assayed with the corresponding stable isotopic labeled standard.
The isotopic-labeled standards are closely related to the structure of the ana-
lyzed amino acids and have similar physicochemical properties to the target amino 
acids, but can be distinguished by mass spectrometry as they have a different 
Figure 8. 
Derivatization of alanine with n-butanol.
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mass to charge ratio (m/z) (Table 8). They are added at a known quantity, and the 
response of each analyzed amino acid is normalized by the response of the match-
ing internal standard. This type of normalization reduces a systematic error due to 
the poor recovery and decreases multiple matrix effects. The inclusion of internal 
standards also corrects a batch to batch variability due to the sample preparation 
and overall raises the accuracy and precision of the assay.
The tandem mass spectrometer has five basic components: the ion source 
where all molecules are a subject to the soft ionization, a mass analyzer that 
separates analytes based on their mass to charge ratio (Q1), a collision cell where 
molecular ions encounter an inert gas and undergo fragmentation (Q2), a second 
mass analyzer to separate fragments produced in the collision cell (Q3), and a 
detector. In collision cell, most of the screened butylated α-amino acids form a 
common and a very specific fragment of 102 Da (Figure 9). The tandem mass 
spectrometer then can be set to scan a constant mass difference of 102 Da and to 
produce a spectrum of the molecular ions derived from those amino acids that lost 
102 Da in the collision cell (Q2) (Figure 9). Butylated amino acids with a basic 
side chains such as ornithine, citrulline loose ammonia and butyl formate in the 
Target amino acid m/z Internal standard m/z
Alanine 146.1 2H4 alanine 150.1
Arginine 231.2 13C,2H4 arginine 236.2
Aspartic acid 246.2 2H3 aspartic acid 249.2
Citrulline 232.2 2H2 citrulline 234.2
Glutamic acid 260.2 2H3 glutamic acid 263.2
Glycine 132.1 15N,13C glycine 134.1
Leucine/isoleucine 188.2 2h3 leucine 191.2
Methionine 206.2 2H3 methionine 209.2
Ornithine 189.2 2H2 ornithine 191.2
Phenylalanine 222.2 13C6 phenylalanine 228.2
Tyrosine 238.2 13C6 tyrosine 244.2
Valine 174.2 2H8 valine 182.2
Table 8. 
Amino acids analyzed by FIA-MS/MS for the standard newborn screening panel and their stable isotopic 
labeled internal standards.
Figure 9. 
Schematic presentation of tandem mass spectrometer. Phenylalanine (as butyl ester) looses 106 Da in the 
collision cell. When mass spectrometer operates in neutral loss scanning mode, it scans Q1 and Q3 in a 
synchronized manner. The mass difference of 102 Da (corresponds to a neutral fragment common to the most 
amino acids) passing through Q2 remains constant.
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collision cell (m/z 119). For glycine and arginine, the most intensive signal corre-
sponds to the loss of 56 and 161 Da, respectively. All these specific losses or transi-
tions can be detected by different and highly specific tandem mass spectrometer’s 
scans in the single analysis.
The main limitation of the FIA-MS/MS is inability to differentiate amino acids 
that share the same m/z such as leucine/isoleucine and hydroxyproline (butylated 
derivatives m/z 188), alanine/sarcosine (butylated derivatives m/z 146) and in a 
more extended profiles glutamine/lysine (butylated derivatives m/z 186), proline/
asparagine (butylated derivatives m/z 172). Also, FIA-MS/MS is not applicable 
for cysteine and homocysteine analysis since these amino acids are not stable and 
react to form cystine and homocystine (Figure 10). During the ionization process, 
cystine and homocystine produce double charged molecules and it complicates the 
analysis.
Due to the high sensitivity and selectivity, there are more mass spectrometry-
based techniques are available for the amino acids analysis, although because of 
extensive sample preparation or limited number of amino acids covered, these 
methods are not widely used in clinical laboratories. Gas chromatography mass 
spectrometry (GCMS) [36], capillary electrophoresis mass spectrometry (CEMS) 
[37], ion pairing (IP)-LC-MS/MS, HILIC-LC-mass spectrometry [38] and two 
column LC-MS/MS methods [39], ion pairing (IP)-LC-HRMS (TOF) [40] can be 
successfully applied for the physiological amino acids analysis although with some 
limitations.
4. Diagnosis of amino acids related disorders
The initial diagnosis of amino acids disorders is based on clinical presentation and 
biochemical findings such as abnormal levels of specific amino acids (Tables 1–6) 
or accumulation of the downstream metabolites in biological fluids, however, these 
characteristics are very heterogenic and often nonspecific. The most common clinical 
indications for the quantitative amino acid analysis in neonates and pediatric patients 
are coma, lethargy, seizures and vomiting, unexplained developmental delay and sib-
lings with similar symptoms. Plasma amino acids analysis is also ordered as a confor-
mational test to follow up abnormal newborn screening results. Hyperammonemia 
is characteristic to the most urea cycle disorders (Table 3) and therefore is another 
Figure 10. 
Sulfur amino acids and their disulfides.
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strong indication for plasma amino acids analysis. Additional general biochemical 
indicators of follow up quantitative amino acids analysis are ketosis (high blood 
and urine ketones), acidosis (blood pH below 7.35) and lactic acidemia (high lactate 
excretion), alkalosis (blood pH above 7.45), polyuria, polydipsia (extreme thirsti-
ness), and dehydration. Amino acids analysis is also an important tool in the diagno-
sis of muscle and liver diseases, neurological disorders, renal failure, autism spectrum 
disorders and nutritional disturbances. Interpretation of amino acids profile is not 
just based on the abnormal level of a single amino acid, but rather involves pattern 
recognition, diagnostic ratios (Tables 1 and 2) and correlation to the patient’s clinical 
history. It is recommended to confirm the diagnosis by molecular analysis or in vitro 
enzymatic assay (usually skin or tissue biopsy sample or blood cells).
5. Treatment options
Currently, there are numbers of available therapeutic approaches that aim in 
a substrate and downstream products restoration balance (Figure 11). One of the 
Figure 11. 
Treatment strategies in amino acids disorders.
Figure 12. 
Removal of toxic ammonia. In urea cycle disorders ammonia cannot be converted to urea, but alternatively 
can be converted to glutamine and glycine. Ammonia scavengers phenylbutyrate and sodium benzoate react 
with glutamine and glycine and consequently remove excess of ammonia. Phenylglutamine and hippurate are 
excreted in urine.
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approaches in this direction is to reduce substrate accumulation by dietary restric-
tions. Nutritional therapies restrict offending amino acid or often total protein 
consumption through provision and monitoring of all essential components to 
meet dietary requirements. For example, special medical foods for PKU affected 
individuals have a very negligible amount of phenylalanine, but supplement the 
total protein required for the normal growth, development and nutritional status. 
Another example is MSUD nutritional management that restricts intake of the 
branch chain amino acids [41], but supplies the majority of the protein required in 
the standard diet.
Amino acids disorders are often manifested by the accumulation of toxic 
downstream metabolites. For example, urea acid disorders are characterized by 
life-threatening hyperammonemia (ammonia accumulation). Toxic metabolites 
removal treatment aims at reducing production or increasing excretion of these 
metabolites. To reduce hyperammonemia, sodium benzoate and phenylbutyrate 
are used to increased ammonia excretion (Figure 12) and to bypass the urea cycle 
metabolic block [42, 43]. Another example is an approach to reduce the produc-
tion of succinylacetone, a neurological toxin that accumulates in tyrosinaemia 
I. Nitisinone (NTBC) treatment blocks a formation of fumarylacetoacetate and its 
subsequent conversion to the succinylacetone [44, 45].
If as a result of mutation, a specific enzyme still retains its residual activity, it 
can be stimulated by a co-factor or a co-factor precursor supplementation. This 
concept applies in treating tetrahydrobiopterin deficiency (Figure 2) [46, 47], 
remethylation defects (Figure 4) [48] and cystathionine beta-synthase deficiency 
(Figure 4) [10]. In some amino acids disorders, even partial metabolic block 
prevents from synthesizing an essential downstream metabolite to meet metabolic 
requirements. In these cases, essential product supplementation is required. For 
example, as a part of urea cycle disorders management, l-arginine and l-citrulline 
are administered [43]. This helps to reduce excessive protein catabolism, due to the 
low arginine levels.
6. Conclusion
In conclusion, amino acids disorders are a group of inborn errors of metabolism 
with highly variable clinical and biochemical presentations. Clinical manifestation 
often comprises severe neurological symptoms, growth and developmental delays. 
Most of the amino acids disorders related conditions are included in the newborn 
screening program to facilitate early diagnosis and early disease treatment. The 
analysis of physiological amino acids levels is a key tool in the diagnosis and clinical 
management of inborn errors of amino acids metabolism. A small subset of amino 
acids is analyzed in newborn screening by tandem mass spectrometry and leads to 
the detection of affected neonates even when they do not have a symptomatic dis-
ease manifestation. A more comprehensive, quantitative amino acids analysis covers 
analysis of nearly 40 amino acids. Prior to the analysis and results interpretation, 
pre-analytical variables such as a fasting status and medication treatments should 
be taken into account in order to avoid false reported findings. A most common 
sample preparation method for the quantitative amino acids analysis is acidification 
of specimen with a known small volume of concentrated acid, such as sulfosali-
cylic acid to precipitate proteins and large molecules, followed by centrifugation, 
leaving the water-soluble amino acids in the supernatant for the analysis. A variety 
of analytical methods have been developed over the past 60 years, and scientists 
have made significant achievements in the fields of derivatization, chromatography 
and mass spectrometry, however, the ion exchange chromatography method still 
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remains the gold standard technique in the field. It is expected that more advanced 
techniques will be developed targeting important clinical laboratories requirements 
such as reduced samples pretreatment, linearity over the large concentration range 
for over the 40 amino acids, increased automation, high sensitivity, shorter run 
time and improved specificity. These methodological improvements will facilitate 
the diagnostic process and therapy monitoring for amino acids disorders. The 
field is also expending to the more exploratory platforms such as a whole-genome 
sequencing and untargeted metabolomics. Although these modalities have some 
restrictions in clinical settings [1, 49], they facilitate novel genes identification, 
novel biomarkers discovery and disease associations and thus strongly advancing 
the field [50, 51].
The major treatment goal for amino acids disorders is to normalize imbalance 
between the substrate and its downstream products and to avoid accumulation of 
the toxic substances. At the same time, nutritional management must meet basic 
dietary requirements for growth and normal development. Even though for many 
amino acids disorders current treatments do not offer a cure, they significantly 
improve the quality of life. It is expected over the upcoming years, that method-
ological advances will lead to a greater understanding of the IEM and in particular 
amino acids related disorders which will help further to improve disease outcomes.
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